Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Compassionate Use for Subcutaneous (SC) Belimumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03125486
Expanded Access Status : No longer available
First Posted : April 24, 2017
Last Update Posted : February 28, 2018
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
GlaxoSmithKline (GSK) have submitted a Biologic License Application (BLA) for the subcutaneous formulation of belimumab which is currently under review by the Food and Drug Administration (FDA). The goal of this individual patient compassionate use supply is to provide a patient with subcutaneous belimumab for the period of 1 year or until the subcutaneous formulation of belimumab becomes approved for use by the FDA and is commercially available to this patient, whichever is sooner. You can access GSK's Policy on Compassionate via http://www.gsk.com/media/3368/compassionate-use.pdf.

Condition or disease Intervention/treatment
Systemic Lupus Erythematosus Drug: SC belimumab 200 mg

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Compassionate Use for Subcutaneous (SC) Belimumab

Resource links provided by the National Library of Medicine

Drug Information available for: Belimumab


Intervention Details:
  • Drug: SC belimumab 200 mg
    Belimumab subcutaneous 200 mg will be supplied for compassionate use for the identified individual subject.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

This is a protocol to support an emergency IND for compassionate use in one patient requiring use of belimumab subcutaneous for SLE treatment (lacks venous access and cannot receive IV belimumab).

Eligibility criteria is based on the following, as provided within GSK's policy on compassionate use:

  • The illness being treated is life threatening or seriously debilitating.
  • There are no satisfactory alternative treatments (confirmed by the HCP).
  • There is sufficient evidence to believe the benefit to the patient justifies the risk You can access GSK's Policy on Compassionate via http://www.gsk.com/media/3368/compassionate-use.pdf.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03125486


Locations
Layout table for location information
United States, Wisconsin
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53215
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline

Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT03125486     History of Changes
Other Study ID Numbers: 207616
First Posted: April 24, 2017    Key Record Dates
Last Update Posted: February 28, 2018
Last Verified: February 2018

Keywords provided by GlaxoSmithKline:
subcutaneous Belimumab
Individual Patient Compassionate Use
SLE
GSK1550188

Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Belimumab
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs